Evidence Based Medicine presented by InpharmD™
InpharmD™
Show overview
Evidence Based Medicine presented by InpharmD™ has been publishing since 2020, and across the 4 years since has built a catalogue of 78 episodes. That works out to roughly 9 hours of audio in total. Releases follow a monthly cadence, with the show now in its 4th season.
Episodes typically run under ten minutes — most land between 6 min and 8 min — and the run-time is fairly consistent across the catalogue. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Health & Fitness show.
The catalogue appears to be on hiatus or wound down — the most recent episode landed 1.7 years ago, with no new episodes in over a year. The busiest year was 2021, with 36 episodes published. Published by InpharmD™.
From the publisher
We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.
Latest Episodes
View all 78 episodes
S4 Ep 11Ketamine for Sickle Cell Disease
InpharmD's EBM podcast focuses on commonly asked drug information questions and the associated literature. This episode focuses on the use of ketamine for Sickle Cell Disease.
Tirzepatide for Sleep Apnea
InpharmD's EBM podcast focuses on commonly asked drug information (DI) questions and the associated literature. Everyday, our queue gets tons of questions asked by health care providers all around the country. For this episode, we assess tirzepatide for obstructive sleep apnea and analyze the SURMOUNT-OSA clinical trials.
Excoriation Disorder
InpharmD's EBM podcast focuses on commonly asked drug information (DI) questions and the associated literature. Everyday, our queue gets tons of questions asked by health care providers all around the country. For this episode, we assess treatment options for excoriation disorder.
S4 Ep 8Phenytoin for Tacrolimus Toxicity
InpharmD's EBM podcast focuses on commonly asked DI questions. Every day, our queue gets tons of new questions asked from providers all around the country. Today's podcast focuses on the use of phenytoin to treat tacrolimus toxicity.
Atypical Antipsychotics and QT–prolongation
InpharmD's EBM podcast focuses on commonly asked drug information questions. Every day, our queue gets tons of new questions asked from providers all around the country. One question that's been garnering a lot of views from our users right now is which atypical antipsychotics are associated with the lowest and highest risk of QT prolongation.
S4 Ep 6Apixaban in Peripheral Artery Disease
Join InpharmD as we discuss the role of apixaban in peripheral artery disease.
Safety and Efficacy of RSV Vaccines
Join InpharmD as we discuss the safety and efficacy of two FDA-approved RSV vaccines, Arexvy and Abrysvo.
S4 Ep 4Safety and Efficacy of Rezafungin
Join us as we discuss the data surrounding newly approved antifungal agent, rezafungin. Interested in learning more? Join our CE on rezafungin on July 27th at 12:00 PM EST - open to all pharmacists!
Perioperative Duloxetine During Orthopedic Surgery for Pain Reduction
Join InpharmD as we discuss the data on perioperative duloxetine (Cymbalta) during orthopedic surgery for pain reduction. Interested in the full data response? Read here!
S4 Ep 2Lecanemab in the treatment of Alzheimer's Dementia
Every month, InpharmD creates a continuing-education (CE) class on the most commonly asked drug information question and the related evidence. Our podcast offers a sneak peak into our CE as we briefly discuss the topic. Episode-2 looks at the safety and efficacy of lecanemab in the treatment of Alzheimer's dementia.
S1 Ep 1Tirzepatide for Weight Loss in Diabetic Patients
Join us as we discuss the evidence surrounding tirzepatide for weight loss in diabetic patient populations.
S4 Ep 2Yet Another Drug Shortage? Alternatives to Oxytocin
Many hospitals have been dealing with the recent oxytocin shortage. With this episode, we discuss possible alternatives and adjuncts to oxytocin, based on the evidence available.
Can Evusheld Increase Cardiovascular Events?
Tune in as we discuss the PROVENT trial and the on-going TACKLE trial to determine whether or not Evusheld can increase cardiovascular events.
S3 Ep 15Could Intermittent Fasting be the Next Big Weight Loss Tool?
A randomized clinical trial conducted to assess time-restricted eating with calorie restriction as compared with daily calorie restriction alone for the effects on weight loss and metabolic risk factors in obese patients.
A 4th Dose of the COVID-19 Vaccine
A regression analysis conducted in Israel showed that a fourth dose appeared to increase the protection against severe illness relative to three doses that were administered more than 4 months earlier. Further studies are needed before applying this to a larger population.
A Possible Alternative for Recurrent Urinary Tract Infections
A multicenter, randomized, open label, non-inferiority trial conducted to test and compare the efficacy of methenamine hippurate for prevention of recurrent urinary tract infections (UTI) with the current standard prophylaxis of daily low dose antibiotics.
Estimation of Breast Cancer Overdiagnosis
A cohort study conducted to estimate the rate of breast cancer overdiagnosis in contemporary mammography practice accounting for the detection of nonprogressive cancer.
Can Ketamine Treat Acute, Severe Suicidal Ideation?
A prospective, double blind, superiority, randomized placebo-controlled trial conducted to confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks.
Could SER-109 be an Answer for Recurrent C.Difficile Infection?
A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.
S3 Ep 9To Boost or not to Boost - That is the Question
A retrospective study conducted to assess for any decrease in mortality associated with the use of the BNT162b2 (BioNTech, Pfizer vaccine) booster.